Showing results (21-30 of 56) with videos related to
Sort By:
Pageof 6
Internal and Emergency Medicine|January 11, 2020
Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomesFrancesco Vizzutti, Filippo Schepis, Umberto Arena, et al.La Radiologia Medica|June 24, 2026
Radiomic MRI model for predicting the development of worrisome features in branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs)Sofia Boccioli, Diletta Cozzi, Domenico Fortunato, et al.Journal of Digestive Diseases|March 31, 2019
Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral centerGabriele Dragoni, Siro Bagnoli, Marco Le Grazie, et al.Annals of Gastroenterology|May 5, 2021
Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center studyMarco Le Grazie, Siro Bagnoli, Gabriele Dragoni, et al.World Journal of Clinical Cases|August 18, 2022
Higher volume growth rate is associated with development of worrisome features in patients with branch duct-intraductal papillary mucinous neoplasmsTommaso Innocenti, Ginevra Danti, Erica Nicola Lynch, et al.World Journal of Hepatology|March 11, 2026
Fatigue and circadian rhythm in non-cirrhotic primary biliary cholangitis: An exploratory comparison with primary sclerosing cholangitis and healthy controlsArmando Curto, Michele Tanturli, Rocco Gabriele Iamello, et al.La Radiologia Medica|February 24, 2023
Branch duct-intraductal papillary mucinous neoplasms (BD-IPMNs): an MRI-based radiomic model to determine the malignant degeneration potentialFederica Flammia, Tommaso Innocenti, Antonio Galluzzo, et al.Journal of Digestive Diseases|September 26, 2022
Pregnancy outcomes in inflammatory bowel disease: Data from a large cohort surveyTommaso Innocenti, Jenny Roselli, Alice Taylor, et al.European Journal of Gastroenterology & Hepatology|January 20, 2022
Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel diseaseTommaso Innocenti, Jenny Roselli, Erica N Lynch, et al.Journal of Crohn'S & Colitis|June 30, 2022
Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicentre Case SeriesBrigida Barberio, Edoardo Savarino, Bram Verstockt, et al.Pageof 6